Proprotein Convertase Subtilisin Kexin 9 Inhibitors

Area of Science:

• Cardiology
• Biochemistry

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a significant risk factor for cardiovascular disease (CVD).
• Lowering LDL-C levels is crucial for reducing the incidence of cardiovascular events.
• Statins are the primary therapy for lipid management, but many patients do not achieve guideline-recommended LDL-C targets.

Purpose of the Study:

• To discuss the role of proprotein convertase subtilisin kexin 9 (PCSK9) in LDL-C regulation.
• To highlight the development of PCSK9 inhibitors as a therapeutic strategy for managing LDL-C levels.

Main Methods:

• Review of scientific literature on LDL-C metabolism and PCSK9 function.
• Discussion of the pharmacological implications of targeting the PCSK9 pathway.

Main Results:

• The PCSK9 pathway plays a critical role in controlling plasma LDL-C concentrations.
• PCSK9 inhibitors have emerged as a promising therapeutic class for further reducing LDL-C.

Conclusions:

• Targeting PCSK9 offers a novel and effective strategy for managing hypercholesterolemia.
• PCSK9 inhibitors provide an important option for patients with refractory hypercholesterolemia or statin intolerance.